Zoetis Inc. (NYSE:ZTS) Shares Acquired by Scientech Research LLC

Scientech Research LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 139.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,773 shares of the company’s stock after purchasing an additional 7,434 shares during the quarter. Zoetis accounts for approximately 0.6% of Scientech Research LLC’s holdings, making the stock its 6th biggest position. Scientech Research LLC’s holdings in Zoetis were worth $2,081,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares during the period. Navigoe LLC bought a new stake in Zoetis during the 4th quarter worth approximately $30,000. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis during the 4th quarter worth approximately $44,000. Finally, Asset Planning Inc bought a new stake in Zoetis during the 4th quarter worth approximately $58,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ZTS shares. Piper Sandler raised their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, May 12th. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Stifel Nicolaus reduced their target price on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $212.75.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Zoetis Trading Up 1.7%

Zoetis stock opened at $163.03 on Friday. The business’s fifty day moving average is $156.46 and its 200 day moving average is $165.43. The stock has a market capitalization of $72.58 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned $1.38 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.